Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
GOOG: 5% | Alphabet Inc shares are trading higher after Berkshire Hathaway disclosed a new stake in the company. ZYME: 61% | Zy...
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab a...
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Equal-Weight and raises the price target fro...
Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.35) by ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced...
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $20 to $23.
